Case Report: Should IGF-1R targeted therapy be revisited in Ewing sarcoma? a report of long-term complete response and review of the literature
This case represents the first report to our knowledge of patient outcomes following IGF-1R and growth hormone inhibition combination. The impressive response observed highlights the clinical synergy of this combination which warrants further clinical exploration as well as the potential of IGF-1R inhibition for ES. Additionally, this case suggests that targeted therapy discontinuation might be an option for select patients with long-term complete remission.
Authors
- Steven Ian Robinson (ORCID: https://orcid.org/0000-0002-1648-1908)
- Scott H. Okuno (ORCID: https://orcid.org/0000-0002-1297-6946)
- Safia K. Ahmed (ORCID: https://orcid.org/0000-0003-2482-594X)
- Matthew T. Houdek (ORCID: https://orcid.org/0000-0003-0390-1018)
- Brittany L. Siontis (ORCID: https://orcid.org/0000-0002-9471-6792)
- Judith Jebastin Thangaiah
- Georgios M. Stergiopoulos (ORCID: https://orcid.org/0009-0009-7315-248X)
- Thanh P. Ho (ORCID: https://orcid.org/0000-0001-7659-5766)
Institutions
- Mayo Clinic (US)
- Mayo Clinic in Arizona (US)
- Mayo Clinic Hospital (US)
- Mayo Clinic in Florida (US)
Publication Details
- Journal
- Frontiers in Oncology
- Published
- 2025-11-19
- DOI
- https://doi.org/10.3389/fonc.2025.1667628
- Primary Topic
- Sarcoma Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Pfizer